ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
| Science & Medicine
ICT01 in combination with low dose IL-2 safely induced substantial γ9δ2 T cell expansion across multiple dosing…
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
| Leadership & Corporate
ImCheck Therapeutics announced today the appointment of Thomas Civik as independent Chairman of its Board of Directors.…
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
| Science & Medicine
ImCheck Therapeutics today announced that it will present data from its Phase I/IIa clinical trial EVICTION-2 in a…
ImCheck Therapeutics is proud to be part of the FT120 for the fourth year in a row!
| Leadership & Corporate
The FT120 aims to support the growth of technology leaders and innovative companies that contribute to France's…
Proud to congratulate ImCheck's scientific founder, Prof. Daniel Olive, on his election as President of the French Society of Immunology
| Leadership & Corporate
We are delighted to share the news that ImCheck’s scientific founder and Clinical Advisory Board member, Prof. Daniel…
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
| Science & Medicine
Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated γ9δ2 T cells, CD8 T cells,…
ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022
| Science & Medicine
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who…
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
| Financial & Business
Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of…
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
| Science & Medicine
Continued positive safety data across a range of ICT01 doses in 69 cancer patients and updated efficacy data from 22…
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
| Science & Medicine
EVICTION trial proceeds to Phase IIa based on promising Phase I patient data for ICT01 across a broad range of solid…
For the third year in a row, ImCheck has been awarded by the French Tech as one of the top 120 French start-ups/scale-ups and among 7 French biotech developing innovative therapies
| Leadership & Corporate
ImCheck has been recognized again as one of the top 120 French start-ups and scale-ups based on performance criteria…
ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference
| Science & Medicine
ImCheck Therapeutics announced today that its Chief Executive Officer, Pierre d’Epenoux, will present a corporate…
ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
| Science & Medicine
Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients…
ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Gamma-delta T Cells in Science Translational Medicine
| Science & Medicine
- Publication underscores ImCheck’s pioneering role in Vγ9Vδ2 T cell-based immunotherapy capable of bridging to the…
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021
| Science & Medicine
ImCheck Therapeutics today announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa…
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
| Science & Medicine
First EVICTION data from checkpoint inhibitor-refractory solid tumor patients treated in the first two…
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
| Science & Medicine
ImCheck Therapeutics today announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa…
ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
| Science & Medicine
- First published study showing the role and sequential interaction of butyrophilin subtypes in the induction of…
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
| Science & Medicine
EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune response of…
ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer
| Leadership & Corporate
ImCheck Therapeutics today announced the appointment of Loui Madakamutil, PhD, as Chief Scientific Officer (CSO). Dr.…